AEON Biopharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that AEON Biopharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.54M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.64M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | $9.10M | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($6.17M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | $164.11M | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($118.02M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($297.71M) | Nov 13, 2024 |
| Q3 | 2024 | Jul 21, 2023 | ($27.66M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($15.38M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($17.64M) | May 14, 2024 |
| Q2 | 2023 | Mar 31, 2023 | ($388.5K) | Jul 21, 2023 |
| Q3 | 2023 | Sep 30, 2022 | ($10.44M) | Mar 29, 2024 |
| Q3 | 2022 | Jun 30, 2022 | $1.87M | Nov 14, 2022 |
| Q2 | 2023 | Jun 30, 2022 | $1.87M | Jul 21, 2023 |
| Q3 | 2022 | Mar 31, 2022 | $2.77M | Nov 14, 2022 |
| Q1 | 2023 | Mar 31, 2022 | $2.77M | May 17, 2023 |
| Q2 | 2023 | Mar 31, 2022 | $2.77M | Jul 21, 2023 |
| Q3 | 2022 | Sep 30, 2021 | $5.66M | Nov 14, 2022 |
| Q3 | 2022 | Jun 30, 2021 | ($4.03M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($4.03M) | Aug 12, 2022 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.49M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.34M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($462.0K) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.02M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | $153.47M | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($74.15M) | May 14, 2025 |
| Q3 | 2023 | Sep 30, 2023 | $64.29M | Mar 29, 2024 |
| Q3 | 2024 | Jul 21, 2023 | ($2.63M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.97M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($13.05M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($9.91M) | Mar 29, 2024 |
| Q2 | 2023 | Jun 30, 2022 | ($427.2K) | Jul 21, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($389.1K) | May 17, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($450.9K) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($398.4K) | Aug 12, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($200.9K) | May 12, 2022 |